News & Views
Deal Secures Supply of Essential Biologicals
Mar 18 2019
Germany-based BioNTech (Mainz), a company focused on supplying critical raw materials for the manufacturing of precise immunotherapy vaccine candidates, has signed a multi-year agreement with Thermo Fisher Scientific for the supply of nucleotides, enzymes and other materials to support BioNTech's messenger RNA (mRNA) manufacturing platform. The four-year, nonexclusive licensing and supply agreement gives BioNTech rights to use Thermo Fisher's technologies as part of its clinical and commercial manufacturing processes.
"Our portfolio of molecular biology products is now enabling development and commercialisation of multiple individualised therapies and other advanced medicines and we continue to expand our capabilities to meet increasing demand," said Gianluca Pettiti, president, biosciences, Thermo Fisher Scientific. "We share BioNTech's commitment to deliver life-saving therapies to patients faster and we look forward to supporting them through clinical trials and post-approval production."
"The relationship with Thermo Fisher Scientific secures our access to customised material essential for the manufacturing and commercialisation of our RNA-based product candidates," said Ugur Sahin, managing director, co-founder and CEO of BioNTech. "In addition, as a life science services leader, Thermo Fisher can also deliver reagents at the scale needed to expand our manufacturing capacities."
No other terms from this transaction were disclosed.
Digital Edition
International Labmate Buyers' Guide 2024/25
June 2024
Buyers' Guide featuring: Product Listings & Manufacturers Directory Chromatography Articles - Enhancing HPLC Field Service with fast-response, non-invasive flowmeters - Digital transformatio...
View all digital editions
Events
Jul 20 2024 Denver, CO, USA
Jul 21 2024 Cape Town, South Africa
Jul 28 2024 San Diego, CA USA
Jul 30 2024 Jakarta, Indonesia
Jul 31 2024 Chengdu, China